Who We Are
Thomas P. Mathers
President and Chief Executive Officer
Tom joined Peptimmune as president and CEO, and director in 2003. He has more than sixteen years of executive management, sales, and marketing experience in the life sciences and medical device industry. Mr. Mathers also serves on the board of directors for the biotechnology industry organization (BIO). Prior to Peptimmune, he served as president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc. Tom also holds one patent for a marketed product and has several other patents pending. He earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War.
Eric H. Zanelli, PhD
Vice President, Research
Dr. Zanelli joined Peptimmune in 2003 as vice president of research and is a leading immunologist and HLA expert with experience in therapeutic development. Prior to Peptimmune, Dr. Zanelli was at Praecis Pharmaceuticals and Cardion AG, applying his expertise in autoimmune disease to the development of new treatments for rheumatoid arthritis, Type I diabetes, and multiple sclerosis. Eric received a PhD in Immunology from the University of Aix-Marseille II, France and was a postdoctoral fellow in the laboratory of Dr. Chella David at the Mayo Clinic, MN. His work was mostly related to the identification of genes involved in antigen processing and the role of MHC Class II gene polymorphism in the predisposition to rheumatoid arthritis. From 1996 to 2001, Eric was assistant professor at the Leiden University Medical Center in the Netherlands. While there, he continued his investigation of the role of MHC Class II genes in predisposition to autoimmune diseases and their value as clinical predictors of disease severity. Eric has over forty publications in peer-reviewed scientific journals.
Carole Cassidy, MBA
Associate Director, Finance and Administration
Carole joined Peptimmune in 2005 and is responsible for all finance and administration. Prior to her role at Peptimmune, Carole worked in real estate development with Baren and Company. She earned her Bachelor's degree in Business Administration from the University of Southern California while on a full academic scholarship, and her Masters in Business Administration from Simmons School of Management.
Dustan Bonnin PAg, MBA
Director, Technology Management & Intellectual Property
Dustan joined Peptimmune in 2003. As director of technology management and intellectual property, Dustan leverages fifteen years of laboratory experience in academic and industrial immunology. Previously at UCSD and Praecis Pharmaceuticals, Dustan is a published author and serial inventor in the field of peptides and peptide copolymers. As a registered Patent Agent and a Babson MBA, Dustan brings a wealth of knowledge and expertise to managing Peptimmune's technologies and intellectual assets.
Michael Fratto
Information Technology
Mike Fratto has been managing Peptimmune's information technology assets since 2003. Mike is a founding partner of Viewpoint Security and works with numerous biotechnology companies in the Cambridge area.
